Clinical Trials Logo

Clinical Trial Summary

Background:

- Patients who have advanced thyroid cancer have a low long-term survival rate. These types of thyroid cancer do not respond well to conventional surgery or radiation, or to specific thyroid cancer treatments such as radioactive iodine treatment and thyroid hormone for thyroid stimulating hormone (TSH) suppression.

- Valproic acid has long been approved as an anticonvulsant to treat seizures in patients with epilepsy. It has also been used to treat bipolar disorder. Recent studies have shown that valproic acid has promising effects in thyroid cancer treatment because it may help destroy cancer cells and help conventional treatments be more effective. However, valproic acid is not approved for thyroid cancer and is therefore an investigational drug.

Objectives:

- To determine whether valproic acid can inhibit tumor growth or induce tumor cell death.

- To determine whether valproic acid can make tumor cells increase their uptake of radioiodine.

Eligibility:

- Individuals at least 18 years of age who have advanced-stage thyroid cancer that is either unresponsive to conventional treatments or fails to absorb radioiodine.

Design:

- Eligible participants will continue on the standard thyroid hormone suppression therapy and begin receiving valproic acid for a total of 10 weeks. Participants will keep a study diary to record doses and side effects, and will have regular clinic visits to provide blood samples and receive additional valproic acid.

- After 10 weeks, participants will have a Thyrogen scan to measure radioiodine uptake after valproic acid therapy. Tumor biopsies and blood samples will be taken at this time.

- If there is increased radioiodine uptake on the scan, participants will have additional radioiodine therapy.

- If there is no increased uptake on the scan, participants will continue on valproic acid for 7 more weeks. After 16 total weeks of treatment, additional blood samples and scans will be taken. Participants may continue to take valproic acid if the thyroid cancer appears to be responding to the treatment.

- Follow-up visits will be scheduled at 3, 6, 9 (for patients continuing on valproic acid only), and 12 months.


Clinical Trial Description

Background:

Patients who have advanced differentiated thyroid cancers (Stage IV) have a five-year survival of only 25%. Clinically this results in more aggressive growth, metastasis, decreased or loss of iodine uptake in the tumor, and tumors that may be refractory to conventional treatment: surgical resection, radioactive iodine treatment and thyroid hormone for Thyroid Stimulating Hormone (TSH) suppression.

In thyroid cancer, valproic acid, at clinically achievable concentrations, has an antiproliferative and differentiating effect.

We hypothesize that valproic acid may inhibit proliferation and induce differentiation in thyroid cancer cells so that 131-I may detect residual disease and be more effective for radioiodine ablation of thyroid cancer cells of follicular cell origin.

Objectives:

The primary goal of this study is to determine if valproic acid will have an antineoplastic and differentiation effect in patients with advanced and or metastatic thyroid cancer of follicular cell origin.

Eligibility:

Unresectable advanced and/or poorly differentiated thyroid cancers of follicular cell origin (excluding anaplastic and medullary thyroid cancer) that have no uptake (less than 1%) on radioiodine scan or are unresponsive to radioiodine therapy.

Elevated serum thyroglobulin (Tg) level (greater than 100ng/ml on thyroid hormone; greater than 10ng/ml off thyroid hormone).

Design:

This will be an open label phase II study to assess the efficacy of valproic acid therapy as an antiproliferative and differentiation agent in patients with incurable differentiated thyroid cancer (unresponsive and/or radioiodine negative and unresectable).

Oral valproic acid will be administered to reach a therapeutic serum level (50 to 100 microgram/ml).

The number of patients to be enrolled is 25 with an interim analysis of response once 13 patients are evaluable for response. It is anticipated that five patients may be enrolled per year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01182285
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 2
Start date September 24, 2010
Completion date April 28, 2016

See also
  Status Clinical Trial Phase
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Recruiting NCT02112370 - Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Phase 3
Not yet recruiting NCT04883294 - Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03484416 - Routine Calcium for Preventing Hypocalcemia N/A
Completed NCT06275425 - Comparison of the Coughing Frequency of Remimazolam Total Intravenous Anesthesia Versus Inhalational Anesthesia N/A
Completed NCT01617694 - Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia N/A
Completed NCT01226914 - A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICELâ„¢ Fibrin Sealant in Thyroidectomy N/A
Completed NCT01137097 - Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Phase 2/Phase 3
Completed NCT03012620 - Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types Phase 2
Completed NCT04574947 - Lidocaine And Neuromonitoring in Thyroid Surgery Phase 4
Completed NCT03392402 - Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules
Completed NCT01308320 - Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Phase 4
Completed NCT05068687 - Peroperative Assessment of Malignancies of the Head and Neck Using High-resolution 18F-FDG-PET/CT N/A
Terminated NCT00647140 - Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Phase 2
Not yet recruiting NCT00385983 - Total Thyroidectomy With Harmonic Scalpel® Phase 4
Completed NCT01103557 - Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma N/A